Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: KHS who wrote (17637)	1/10/1999 11:42:00 PM
From: Mkilloran	Respond to of 23519

KHS...its very clear that the milestone payments are only paid after Italy, France, Germany and Spain licence MUSE it's all in the 10k....there is no delay just confusion what approval in the UE is vrs licence in each country after UE approval. There still looking for a partner .....see what the conf call brings in 2 weeks. Factory was approved ...waiting on the FDA.....reality PFE comes before VVUS in the FDA's pecking order...is that fair ..no but Vivus was at the mercy of the FDA . Astra and Janssen have up to 1 year after a country is approved for them to start a sales campaign....the good news that Astra and Janssen have been moving very well...no delays on their part. The reality...Viagra took a much bigger piece of the market than anyone thought. Cutbacks/layoffs down to one shift...best thing they can do to control cost till sales pick up with more countries approved. Writeoffs is a great thing that the new CFO pushed..clear the plate in 1998. It's a small company that made mistakes.......IMO those mistakes are behind us. They need to get a USA partner...that's the priority. If they do they can demonstrate they can capture 10% of the market build up to 100,000 scripts a week worlkwide late 1999...be profitable..That will help the stock price.. Them move forward with Alibra ,gene therapy, etc or sell the company for a good price.